|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||20.25 - 20.80|
|52 Week Range||8.80 - 25.70|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.86|
Solodyn has an indication for the treatment of inflammatory lesions of moderate to severe acne in patients 12 years and older. The generic version of Solodyn is the ninth generic tetracycline-class drug in Teva’s portfolio. According to IMS data, Solodyn Extended Release 65 mg and 115 mg tablets generated sales of ~$148 million in the United States in 2017.
BRIDGEWATER, N.J. , March 14, 2018 /PRNewswire/ -- Amneal Pharmaceuticals has received FDA approval for Erythromycin Tablets USP, 250 mg and 500 mg strengths. The Amneal product is a therapeutic equivalent ...
Impax Laboratories Inc went to trial on Monday over allegations by major retailers and consumers that the company agreed to delay launching a generic version of acne medication Solodyn in exchange for millions of dollars from the manufacturer. The trial in Boston federal court is one of a handful to have taken place since the U.S. Supreme Court in 2013 said so-called "pay-for-delay" settlements resolving pharmaceutical patent lawsuits can violate antitrust laws. A lawyer for Impax, in his opening statement, denied there was any such arrangement to delay Solodyn's entry to the market.
Impax Laboratories Inc went to trial on Monday over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication's manufacturer. Jury selection began in Boston federal court in a case centered on an alleged "pay-for-delay" settlement, in which a generic manufacturer agrees to resolve legal challenges to a brand-name drug's patents and delay making a cheaper version. The trial is one of a handful to have taken place since the U.S. Supreme Court in 2013 said that such settlements, which also involve brand-name drug companies paying the generic manufacturers, can be found to be anticompetitive.
Impax Laboratories Inc has agreed to pay $35 million to resolve part of litigation over claims it entered into an anticompetitive deal in a patent case to delay releasing a generic version of the acne medication Solodyn. The settlement was disclosed in papers filed in federal court in Boston on Saturday. It resolved part of the antitrust litigation Impax faces over Solodyn related to sales of the drug to direct purchasers such as retailers and wholesalers.
Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.
BRIDGEWATER, N.J., March 7, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (IPXL) today announced that they will jointly present at the Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami, Florida on Tuesday, March 13, 2018 at 2:35 p.m. ET. Paul Bisaro, President and CEO of Impax, Bryan Reasons, Senior Vice President and Chief Financial Officer of Impax, and Robert Stewart, President of Amneal Pharmaceuticals will participate in a fireside chat. To access a live webcast of the presentation, visit Impax's Investor Relations Web site at https://investors.impaxlabs.com/Investor-Relations.
Moody's Investors Service, ("Moody's") rated Amneal Pharmaceuticals, LLC's ("Amneal") proposed $2.7 billion senior secured term loan B1. Moody's also affirmed Amneal's current ratings ...
Impax (IPXL) reports dismal fourth-quarter results with earnings and sales coming in lower than the year-ago period as well as the estimates.
Adamis’ Symjepi was billed as an EpiPen competitor, but the company’s search for a commercialization partner has prevented it from coming to market.
Impax Laboratories Inc (NASDAQ:IPXL), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGS over the last few months. AsRead More...
The Hayward, California-based company said it had a loss of $4.18 per share. Earnings, adjusted for one-time gains and costs, came to 11 cents per share. The results did not meet Wall Street expectations. ...
BRIDGEWATER, N.J. , March 1, 2018 /PRNewswire/ -- Amneal Pharmaceuticals has launched oseltamivir phosphate for oral suspension, the company's AB-rated therapeutic equivalent for Tamiflu ® , in a 6 mg/mL ...
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Impax Laboratories, Inc. (NASDAQ: IPXL ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018 at 8:30 AM Eastern Time. ...
- Q4 2017 Total Revenues of $183 Million ; GAAP Net Loss Per Share of $4.18 ; Non-GAAP Adjusted Income Per Share of $0.11 - - Full Year 2017 Total Revenues of $776 Million ; GAAP Net Loss Per Share of ...
Impax Laboratories (IPXL) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Impax Laboratories Inc’s (NASDAQ:IPXL): Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. With the latest financial year loss of -US$472.03M and a trailing-twelve monthRead More...
NEW YORK, Feb. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Timken ...
BRIDGEWATER, N.J. , Feb. 21, 2018 /PRNewswire/ -- Amneal Pharmaceuticals has launched memantine hydrochloride extended-release capsules, the company's AB-rated equivalent for Namenda XR ® , in 7 mg, 14 ...
Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments.
BRIDGEWATER, N.J., Feb. 6, 2018 /PRNewswire/ -- Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (IPXL), today announced that Andrew S. Boyer, 52, has joined Amneal as Executive Vice President, Commercial Operations and is expected to serve in the same capacity for the new combined company following the consummation of the combination with Impax. "We are pleased that Andy has joined Amneal and will be leading our commercial organization," said Chirag Patel, Co-CEO and chairman, Amneal Pharmaceuticals. Mr. Boyer will work closely with Chirag and Chintu Patel, Amneal's current Co-CEOs, and Rob Stewart, President of Amneal and the future CEO of the new Amneal, to further enhance its business in preparation for the pending combination with Impax, which is currently expected to occur in the first half of 2018.
BRIDGEWATER, N.J. , Feb. 5, 2018 /PRNewswire/ -- Amneal Pharmaceuticals has launched methylphenidate hydrochloride extended-release tablets, USP (CII) in 18, 27, 36, and 54 mg strengths. Amneal's methylphenidate ...